A new grand bargain to improve the antimicrobial market for human health

The working group’s final report highlights the stark disparity in research on policy issues relevant to LMICs when compared with high-income countries (HICs), with less than 10 percent of the academic literature examined focusing on the former group. Different stakeholders have very different policy priorities, with those in HICs more inclined to emphasize the need for innovative new drugs while LMIC policymakers view access as a much greater priority. Countries often think it is not in their interest to implement policies that most agree all countries would benefit from. Global cooperation is needed to overcome collective action problems.